Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to improving the health and wellness of people and the planet through a novel and innovative approach to impact investing, announced the sale of its cannabinoid drug development business as part of its strategic plan to focus on acquiring, reclaiming and repurposing mine land throughout Appalachia. On September 30, 2024, the Company sold all of the common stock of its wholly-owned subsidiary, Graphium Biosciences, Inc. (“Graphium”), to Placer Biosciences, Inc. (“Placer”), a newly-formed biotech drug development company led by Dr. Brandon Zipp and Richard McKilligan, Graphium’s Chief Science Officer and Chief Financial Officer, respectively.
Read the full article: Range Impact Announces Sale of Cannabinoid Drug Development Business //
Source: https://www.globenewswire.com/news-release/2024/10/02/2957343/0/en/Range-Impact-Announces-Sale-of-Cannabinoid-Drug-Development-Business.html